Anticoagulation therapy | UFH | LMWH | Fondaparinux |
---|---|---|---|
Nomenclature | Unfractionated heparin | Two LMWHs based formulation (1) dalteparin (Fragmin®) and (2) enoxaparin (Lovenox®) | Fondaparinux (Arixtra®) |
Mechanism of action | Bind to AT and increases the affinity of AT to bind and inactivate both Fxa and thrombin | Bind to AT and increases the affinity of AT to bind and inactivate Fxa. The effect on inactivation of thrombin is relatively less. | Bind to AT and increases the affinity of AT to bind and inactivate Fxa. |
Half life | 60–120 min | (4–7 h) Enoxaparin 2–5 (dalteparin) | 17–21 h |
Neutralization with protamine sulfate | Yes | Yes | -NA- |
Clearance | Hepatic & Reticulo-endothelial system No renal adjustments | Renal | Renal |
Ability to cause HIT | Yes | Yes | Low; Cases reported |